ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent Gingival Bleeding After Scaling: A Diagnostic Clue to von Willebrand Disease.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThe 2021 ASH/ISTH/NHF/WFH VWD diagnosis guidelines recommend Type 1 VWD diagnoses for patients with (a) VWF <0.30 IU/mL or (b) 'Low VWF' 0.30-0.50 IU/mL with the presence of abnormal bleeding. This recommendation recategorizes 'Low VWF' patients with abnormal bleeding into Type 1 VWD.
aimTo assess the impact of the 2021 VWD guidelines on the diagnosis and management of 'Low VWF' patients.
methodsA single centre retrospective study was conducted to review all patients presenting for VWD evaluation between January 2000 to September 2024, analyzing for clinical features, ISTH-BAT scores, VWF/FVIII levels, and management of bleeding. 149 patients, totalling 305 clinical encounters, were included in the study.
resultsSeventy five percent of patient encounters had a change in diagnosis from 'Low VWF' to Type 1 VWD after applying the 2021 VWD diagnosis guidelines. The use of VWF therapy (statistically significant, p = 0.04) and antifibrinolytics (not statistically significant, p = 0.52) increased in the post-guidelines period compared to pre-guidelines period. More than half saw increasing VWF levels with age, emphasizing the need to periodically re-evaluate/re-test patients with 'Low VWF'.
conclusionApplying the 2021 VWD guidelines leads to improved diagnosis and management of symptomatic patients with 'Low VWF' as they are now classified as Type 1 VWD and receive optimal care with increased use of haemostatic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.